

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

INDIVIOR INC., INDIVIOR UK LIMITED,  
and AQUESTIVE THERAPEUTICS, INC.,

Plaintiffs,

v.

MYLAN TECHNOLOGIES INC., MYLAN  
PHARMACEUTICALS INC. and MYLAN  
N.V.,

Defendants.

C.A. No. 15-1016-RGA

INDIVIOR INC., INDIVIOR UK LIMITED,  
and AQUESTIVE THERAPEUTICS, INC.,

Plaintiffs,

v.

ALVOGEN PINE BROOK, LLC,

Defendant.

C.A. No. 15-0477-RGA

**NOTICE OF APPEAL BY PLAINTIFFS  
INDIVIOR INC., INDIVIOR UK LIMITED, AND AQUESTIVE THERAPEUTICS, INC.**

Notice is hereby given that, pursuant to Federal Rule of Appellate Procedure 4(a)(3), Plaintiffs Indivior Inc., Indivior UK Limited, and Aquestive Therapeutics, Inc. hereby appeal to the United States Court of Appeals for the Federal Circuit from the Final Judgment dated May 8, 2018 (ECF No. 293 in C. A. No. 15-1016-RGA) as to Defendant Alvogen Pine Brook, LLC, together with the Trial Opinion (ECF No. 283 in C.A. 15-1016-RGA), Stipulation and [Proposed] Order (ECF No. 239 in C.A. 15-1016-RGA) as “SO ORDERED” by the Court on September 27, 2017, the Markman Order (ECF No. 93 in C.A. No. 15-1016-RGA), the

Memorandum Opinion Providing Claim Construction for Multiple Terms (ECF No. 87 in C.A. 15-1016-RGA), along with all adverse findings, holdings, rulings, determinations, conclusions, orders, claim constructions, opinions, and decisions leading thereto or merged or incorporated therein, including, but not limited to

- Markman Order (ECF No. 179 in C.A. No. 14-1451-RGA),
- Markman Order (ECF No. 166 in C.A. No. 13-1674-RGA),
- Memorandum Opinion Providing Claim Construction for Multiple Terms (ECF No. 175 in C.A. No. 14-1451-RGA),
- Memorandum Opinion Providing Claim Construction for Disputed Terms (ECF No. 156 in C.A. 13-1674-RGA),

and any and all subsidiary findings and conclusions of the District Court.

Included herewith pursuant to Federal Rule of Appellate Procedure 3(e) is payment of the filing fee (\$5.00) as required by 28 U.S.C. § 1917 and the docketing fee (\$500.00) as required by Federal Circuit Rules 52(a)(2) and 52(a)(3).

Dated: May 9, 2018

Respectfully submitted,

OF COUNSEL:

Daniel A. Ladow  
James M. Bollinger  
Timothy P. Heaton  
J. Magnus Essunger  
TROUTMAN SANDERS LLP  
875 Third Avenue  
New York, New York 10022  
(212) 704-6000  
daniel.ladow@troutman.com  
james.bollinger@troutman.com  
timothy.heaton@troutman.com  
magnus.essunger@troutman.com

/s/ Mary W. Bourke  
Mary W. Bourke (#2356)  
Dana K. Severance (#4869)  
Daniel M. Attaway (#5130)  
Womble Bond Dickinson (US) LLP  
222 Delaware Avenue, Suite 1501  
Wilmington, DE 19801  
(302) 252-4320  
(302) 252-4330 (Fax)  
mary.bourke@wbd-us.com  
dana.severance@wbd-us.com  
daniel.attaway@wbd-us.com

*Counsel for Plaintiffs*

*Counsel for Plaintiffs Indivior Inc. & Indivior  
UK Limited*

Erica N. Andersen  
Jeffrey B. Elikan  
Jeffrey H. Lerner  
COVINGTON & BURLING LLP  
One CityCenter  
850 Tenth Street, NW  
Washington, D.C. 20001  
(202) 662-6000  
eandersen@cov.com  
jelikan@cov.com  
jlerner@cov.com

*Counsel for Plaintiffs Indivior Inc. & Indivior  
UK Limited*

Cassandra A. Adams  
STEPTOE & JOHNSON LLP  
1114 Avenue of the Americas  
New York, New York 10036  
(212) 506-3900  
cadams@steptoe.com

James F. Hibey  
STEPTOE & JOHNSON LLP  
1330 Connecticut Avenue, NW  
Washington, DC 20036

(212) 429-3000  
jhibey@steptoe.com

*Counsel for Plaintiff Aquestive Therapeutics,  
Inc.*